research use only

Iberdomide (CC-220) CELMoD

Name: Iberdomide (CC-220)
Brand: Selleck Chemicals
SKU: S8760
Availability: InStock
Rating: 5 (13 reviews)

Cat.No.S8760

Iberdomide (CC-220) is a novel oral immunomodulatory compound that targets cereblon, part of the CRL4CRBN E3 ubiquitin ligase complex, with an IC50 of 60 nM in a competitive TR-FRET assay. Iberdomide (CC-220) induces apoptosis with antitumor and immunostimulatory activities.

Chemical Structure

Molecular Weight: 449.50

Jump to

Quality Control

Batch: Purity: 99.75%

99.75

Related Targets	PD-1/PD-L1 CXCR STING AhR Immunology & Inflammation related CD markers Interleukins Anti-infection Antioxidant COX
Other E3 Ligase Inhibitors	Skp2 inhibitor C1 (SKPin C1) Apcin Avadomide (CC-122) PRT4165 VL285 SZL P1-41 CC-90009 VH298 Mezigdomide (CC-92480) Homo-PROTAC cereblon degrader 1

Solubility

In vitro
Batch:

DMSO : 90 mg/mL (200.22 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 5 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	449.50	Formula	C₂₅H₂₇N₃O₅	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	1323403-33-3	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			SMILES	C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3OCC4=CC=C(C=C4)CN5CCOCC5

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	cereblon 60 nM
In vitro	Iberdomide (CC-220) is a potent anti-proliferative and pro-apoptotic compound that shows activity in several MM cell line categories. In cellular degradation assays, treatment with this compound results in the loss of Ikaros protein levels with an EC50 of 1 nM. It is similarly potent toward Aiolos, with an EC50 of 0.5 nM. It induces PBMC-mediated killing of all MM cell lines regardless of the level of Cereblon expression and cell autonomous sensitivity. This compound acts through binding of Cereblon, leading to the degradation of the hematopoietic transcription factors Ikaros and Aiolos, followed by disruption of the MM promoting c-Myc/IRF4 axis.
References	[1] https://pubmed.ncbi.nlm.nih.gov/28425720/ [2] http://www.bloodjournal.org/content/128/22/1591?sso-checked=true [3] https://pubmed.ncbi.nlm.nih.gov/34258584/

Applications

Methods	Biomarkers	Images	PMID
Western blot	Aiolos / Ikaros IKZF1 / IKZF3 / ZFP91 / CK1α / CBRN / UBE2G1		28848067

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-05-12)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06896916	RECRUITING	Multiple Myeloma	AbbVie	2025-08-07	PHASE1
NCT06892522	RECRUITING	Multiple Myeloma	AbbVie	2025-06-30	PHASE1; PHASE2
NCT07624513	NOT_YET_RECRUITING	Multiple Myeloma	Dana-Farber Cancer Institute	2026-06-08	PHASE3
NCT06762769	RECRUITING	Smouldering Myeloma	University College, London	2025-06-02	PHASE2
NCT06785415	RECRUITING	Recurrent Multiple Myeloma	Mayo Clinic	2025-03-18	PHASE1; PHASE2
NCT04998786	ACTIVE_NOT_RECRUITING	Multiple Myeloma at First Relapse	Nantes University Hospital	2021-12-14	PHASE2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):